This page in English

Lars Rydén

Professor

Besöksadress : Karolinska Universitetssjukhuset, Solna, S1:02 171 76 Stockholm
Postadress : Institutionen för medicin, Solna (MedS), K2, Forskargrupp L Rydén, Karolinska Universitetssjukhuset, Solna, S1:02 171 76 Stockholm
Leveransadress : Karolinska Universitetssjukhuset, Solna, S1:02 171 76 Stockholm

Forskningsbeskrivning

Sedan 10-15 år tillbaka driver forskargruppen kring professor Lars Rydén kliniskt inriktad forskning inom området diabetes och hjärtinfarkt och har byggt upp en stor kunskapsmassa inom området.

Läs mer på gruppens webbsida

 

Publikationer

Corrections needed to 2016 ESC and AHA guidelines on heart failure
Rydén L, Van De Werf F, Armstrong Pw, Mcguire Dk, Standl E, Peterson Ed, et al
The lancet. Diabetes & endocrinology 2017;5(5):325-326

Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort
Ritsinger V, Brismar K, Malmberg K, Mellbin L, Näsman P, Rydén L, et al
Diabetes & vascular disease research 2017;14(2):77-87

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
Standl E, Schnell O, Mcguire Dk, Ceriello A, Rydén L
The lancet. Diabetes & endocrinology 2017;5(5):391-402

Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients
Rathnayake N, Buhlin K, Kjellström B, Klinge B, Löwbeer C, Norhammar A, et al
Journal of clinical periodontology 2017;44(7):692-699

The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial
Van Steen Sc, Schrieks Ic, Hoekstra Jb, Lincoff Am, Tardif Jc, Mellbin Lg, et al
European journal of preventive cardiology 2017;24(8):858-866

Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
Rydén L, Shahim B, Mellbin L
Clinical therapeutics 2016;38(6):1279-87

Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study
Arnetz L, Hage C, Brismar K, Catrina Sb, Norhammar A, Lundman P, et al
Diabetes & vascular disease research 2016;13(4):307-11

Current perspectives on cardiovascular outcome trials in diabetes
Schnell O, Rydén L, Standl E, Ceriello A, D&cvd Easd Study Group
Cardiovascular diabetology 2016;15(1):139-

Effects of enhanced external counterpulsation on skeletal muscle gene expression in patients with severe heart failure
Melin M, Montelius A, Rydén L, Gonon A, Hagerman I, Rullman E
Clinical physiology and functional imaging 2016;():-

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, et al
European journal of preventive cardiology 2016;23(6):636-48

Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF)
Makubi A, Hage C, Sartipy U, Lwakatare J, Janabi M, Kisenge P, et al
International journal of cardiology 2016;220():750-8

Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys
De Backer G, De Bacquer D, Rydén L, Kotseva K, Gaita D, Georgiev B, et al
European journal of preventive cardiology 2016;23(15):1618-27

Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions
Kotseva K, De Bacquer D, De Backer G, Rydén L, Jennings C, Gyberg V, et al
European journal of preventive cardiology 2016;23(18):2007-2018

Oral glucose tolerance testing and cardiovascular disease
Rydén L, Viveca G, Schnell O, Jaakko T, Euroaspire Iv Investigators
The lancet. Diabetes & endocrinology 2016;4(9):732-3

Periodontal disease - important to consider in cardiovascular disease prevention
Kjellström B, Rydén L, Klinge B, Norhammar A
Expert review of cardiovascular therapy 2016;14(9):987-9

Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study
Rydén L, Buhlin K, Ekstrand E, De Faire U, Gustafsson A, Holmer J, et al
Circulation 2016;133(6):576-83

Problems, Pitfalls and Encouraging Information on Patients with Diabetes and Heart Failure
Norhammar A, Johansson I, Rydén L
Cardiology 2016;134(4):411-2

Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A
Journal of the American College of Cardiology 2016;68(13):1404-1416

Response by Rydén to Letter Regarding Article, "Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study"
Rydén L
Circulation 2016;134(1):e2-

Symptoms of depression and their relation to myocardial infarction and periodontitis
Kjellström B, Gustafsson A, Nordendal E, Norhammar A, Nygren Å, Näsman P, et al
European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology 2016;():1474515116686462-

Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV
Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Tuomilehto J, et al
BMJ open 2016;6(12):e013835-

Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013
Kotseva K, De Bacquer D, Jennings C, Gyberg V, De Backer G, Rydén L, et al
Global heart 2016;():-

Treatment of diabetes and heart failure: joint forces
Swedberg K, Rydén L
European heart journal 2016;37(19):1535-7

Accuracy of a Simplified Glucose Measurement Device--The HemoCue Glucose 201RT
Segerhag E, Gyberg V, Ioannides K, Jennings C, Rydén L, Stagmo M, et al
Diabetes technology & therapeutics 2015;17(10):755-8

Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study
Gyberg V, Kotseva K, Dallongeville J, Backer Gd, Mellbin L, Rydén L, et al
European journal of preventive cardiology 2015;22(6):753-61

EURObservational research programme: EUROASPIRE The EUROASPIRE survey of cardiovascular prevention and diabetes in 24 countries in Europe
Kotseva K, Ryden L, De Backer G, De Bacquer D, Wood D
EUROPEAN HEART JOURNAL 2015;36(16):950-1

Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology
Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al
Cardiovascular diabetology 2015;14():133-

Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure
Makubi A, Hage C, Lwakatare J, Mmbando B, Kisenge P, Lund Lh, et al
Heart (British Cardiac Society) 2015;101(8):592-9

Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes
Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A
Heart (British Cardiac Society) 2015;101(14):1139-48

Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease)
Rathnayake N, Gustafsson A, Norhammar A, Kjellström B, Klinge B, Rydén L, et al
PloS one 2015;10(7):e0126370-

Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology
Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Sundvall J, et al
European heart journal 2015;36(19):1171-7

Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort
Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, et al
Diabetes & vascular disease research 2015;12(1):23-32

Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study
Makubi A, Hage C, Lwakatare J, Kisenge P, Makani J, Rydén L, et al
Heart (British Cardiac Society) 2014;100(16):1235-41

Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls
Mohammad Aa, Rahbar A, Lui Wo, Davoudi B, Catrina A, Stragliotto G, et al
PloS one 2014;9(12):e113740-

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial
Lincoff Am, Tardif Jc, Schwartz Gg, Nicholls Sj, Rydén L, Neal B, et al
JAMA 2014;311(15):1515-25

ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary
Dev Collaboration European Assoc, Esc, Task Force Diabet Prediabet, Ryden L, Grant Pj, Anker Sd, et al
DIABETES & VASCULAR DISEASE RESEARCH 2014;11(3):133-73

Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial
Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A
The lancet. Diabetes & endocrinology 2014;2(8):627-33

Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry
Johansson I, Edner M, Dahlström U, Näsman P, Rydén L, Norhammar A
European journal of heart failure 2014;16(4):409-18

Longitudinal development of left ventricular diastolic function in patients with type 2 diabetes
Venskutonyte L, Jarnert C, Rydén L, Kjellström B
Diabetes care 2014;37(11):3092-7

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Holman Rr, Bethel Ma, Chan Jc, Chiasson Jl, Doran Z, Ge J, et al
American heart journal 2014;168(1):23-9.e2

SURF - SUrvey of Risk Factor management: first report of an international audit
European Assoc Cardiovasc, Surf Investigators, Cooney Mt, Reiner Z, Sheu W, Ryden L, et al
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2014;21(7):813-22

The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management
Katz P, Leiter La, Mellbin L, Rydén L
Diabetes & vascular disease research 2014;11(6):395-409

The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study
Hage C, Brismar K, Lundman P, Norhammar A, Ryden L, Mellbin L
DIABETES & VASCULAR DISEASE RESEARCH 2014;11(4):290-293

2013 ESH/ESC Guidelines for the management of arterial hypertension
Task Force Members, Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al
EUROPEAN HEART JOURNAL 2013;34(28):2159-219

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Origin Trial Investigators, Mellbin Lg, Ryden L, Riddle Mc, Probstfield J, Rosenstock J, et al
EUROPEAN HEART JOURNAL 2013;34(40):3137-44

Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial
Mann Jf, Anderson C, Gao P, Gerstein Hc, Boehm M, Rydén L, et al
Journal of hypertension 2013;31(2):414-21

Early achievements in cardiovascular care as reflected in the Journal of Internal Medicine
Rydén L
Journal of internal medicine 2013;274(6):529-40

Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)
Grace Origin Investigators, Lonn Em, Bosch J, Diaz R, Lopez-jaramillo P, Ramachandran A, et al
DIABETES CARE 2013;36(9):2466-74

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Easd, Esc, Ryden L, Grant Pj, Anker Sd, Berne C, et al
EUROPEAN HEART JOURNAL 2013;34(39):3035-87

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Europejskim Towarzystwem Badan Nad, Ryden L, Grant Pj, Anker Sd, Berne C, Cosentino F, et al
KARDIOLOGIA POLSKA 2013;:S319-94

Evaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
Alecardio Study Investigators, Lincoff Am, Tardif Jc, Neal B, Nicholls Sj, Ryden L, et al
AMERICAN HEART JOURNAL 2013;166(3):429-34

Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes
Hage C, Lundman P, Rydén L, Mellbin L
European journal of preventive cardiology 2013;20(4):549-54

Long-term impact of postconditioning on infarct size and left ventricular ejection fraction in patients with ST-elevation myocardial infarction
Sörensson P, Rydén L, Saleh N, Tornvall P, Arheden H, Pernow J
BMC cardiovascular disorders 2013;13():22-

Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: a DIGAMI2 QoL sub-study
Venskutonyte L, Brismar K, Rydén-bergsten T, Rydén L, Kjellström B
Diabetes & vascular disease research 2013;10(3):263-9

Self-rated health predicts outcome in patients with type 2 diabetes and myocardial infarction: a DIGAMI 2 quality of life sub-study
Venskutonyte L, Brismar K, Öhrvik J, Rydén L, Kjellström B
Diabetes & vascular disease research 2013;10(4):361-7

Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study
Hage C, Brismar K, Efendic S, Lundman P, Rydén L, Mellbin L
Journal of internal medicine 2013;273(4):410-21

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial
Mellbin Lg, Malmberg K, Rydén L, Wedel H, Vestberg D, Lind M
European heart journal 2013;34(5):374-9

Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction
Jung C, Sorensson P, Saleh N, Arheden H, Ryden L, Pernow J
ATHEROSCLEROSIS 2012;221(1):226-31

Effects of Myocardial Postconditioning on the Recruitment of Endothelial Progenitor Cells
Jung C, Sorensson P, Saleh N, Arheden H, Ryden L, Pernow J
JOURNAL OF INTERVENTIONAL CARDIOLOGY 2012;25(2):103-10

European guidelines for cardiac and vascular disease prevention in clinical practice for 2012
Czlonkowie Grp Roboczej, Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al
KARDIOLOGIA POLSKA 2012;:S1-S99

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
European Assoc Cardiovascular Prev, Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al
EUROPEAN HEART JOURNAL 2012;33(13):1635-701

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren Wmm, et al
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2012;19(4):585-667

European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Eacpr, Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE 2012;19(4):403-88

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Eacpr, Chairperson Jp, De Backer G, Gohlke H, Graham I, Reiner Z, et al
ATHEROSCLEROSIS 2012;223(1):1-68

Evidence for a beneficial effect of glucose-insulin-potassium in patients with acute coronary syndromes: Did the IMMEDIATE trial solve an unanswered question?
Mellbin L, Rydén L
Expert review of cardiovascular therapy 2012;10(9):1097-9

Glucose perturbations and cardiovascular risk: challenges and opportunities
Rydén L, Mellbin L
Diabetes & vascular disease research 2012;9(3):170-6

Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?
Rydén L, Mellbin L
Current vascular pharmacology 2012;10(6):690-2

Measuring risk online--feasibility of using FINDRISC in an online workplace survey
Gyberg V, Hasson D, Tuomilehto J, Rydén L
Primary care diabetes 2012;6(2):103-7

Mortality prediction in the elderly by an easily measured metabolic index
Venskutonyte L, Rydén L, Nilsson G, Ohrvik J
Diabetes & vascular disease research 2012;9(3):226-33

Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study
Jarnert C, Kalani M, Rydén L, Böhm F
Diabetes & vascular disease research 2012;9(4):287-95

Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)
Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al
CIRCULATION 2011;124(16):1727-36

Bringing prevention to the population: an important role for cardiologists in policy-making
O'kelly S, Andersen K, Capewell S, Ryden L
EUROPEAN HEART JOURNAL 2011;32(16):1964-7

Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes The TRANSCEND study
Transcend Investigators, Barzilay Ji, Gao P, Ryden L, Schumacher H, Probstfield J, et al
DIABETES CARE 2011;34(9):1902-7

Policymakers' perceptions of cardiovascular health in Europe
Gyberg V, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2011;18(5):745-53

Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study
Digami 2 Investigators, Mellbin Lg, Malmberg K, Norhammar A, Wedel H, Ryden L
DIABETOLOGIA 2011;54(6):1308-17

The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes
Hage C, Grip L, Malmberg K, Ryden L, Wallander M, Saleh N
DIABETES & VASCULAR DISEASE RESEARCH 2011;8(2):143-9

Assessment of myocardium at risk with contrast enhanced steady-state free precession cine cardiovascular magnetic resonance compared to single-photon emission computed tomography
Sorensson P, Heiberg E, Saleh N, Bouvier F, Caidahl K, Tornvall P, et al
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE 2010;:25-

Copeptin, IGFBP-1, and Cardiovascular Prognosis in Patients With Type 2 Diabetes and Acute Myocardial Infarction A report from the DIGAMI 2 trial
Mellbin Lg, Ryden L, Brismar K, Morgenthaler Ng, Ohrvik J, Catrina Sb
DIABETES CARE 2010;33(7):1604-6

Diabetes, prediabetes and cardiovascular risk
Mellbin Lg, Anselmino M, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2010;:S9-14

Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes
Venskutonyte L, Malmberg K, Norhammar A, Wedel H, Ryden L
JOURNAL OF INTERNAL MEDICINE 2010;268(1):75-82

Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction
Sorensson P, Saleh N, Bouvier F, Bohm F, Settergren M, Caidahl K, et al
HEART 2010;96(21):1710-5

Gluco-metabolic risk factors and survival in elderly
Venskutonyte L, Nilsson G, Ryden L, Ohrvik J
EUROPEAN HEART JOURNAL 2010;:524-524

Glucose Monitoring by Means of an Intravenous Microdialysis Catheter Technique
Hage C, Mellbin L, Ryden L, Wernerman J
DIABETES TECHNOLOGY & THERAPEUTICS 2010;12(4):291-5

Insulin in patients with acute myocardial infarction and diabetes, friend or foe? A report from the Digami 2 study
Mellbin L, Malmberg K, Norhammar A, Wedel H, Ryden L
EUROPEAN HEART JOURNAL 2010;:343-344

Insulin in patients with acute myocardial infarction and diabetes - friend or foe? A report from the DIGAMI 2 study
Mellbin Lg, Malmberg K, Norhammar A, Wedel H, Ryden L
DIABETOLOGIA 2010;:S22-S22

Mannose-binding lectin genotype and phenotype and their impact on cardiovascular prognosis in patients with type 2 diabetes and myocardial infarction; a report from the DIGAMI 2 trial
Mellbin L, Ryden L, Hamsten A, Malmberg K, Steffensen R, Ohrvik J, et al
EUROPEAN HEART JOURNAL 2010;:345-345

Mannose-Binding Lectin Genotype and Phenotype in Patients With Type 2 Diabetes and Myocardial Infarction
Mellbin Lg, Hamsten A, Malmberg K, Steffensen R, Ryden L, Ohrvik J, et al
DIABETES CARE 2010;33(11):2451-6

NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study
Gustafsson I, Mellbin L, Dickstein K, Malmberg K, Ryden L, Torp-pedersen C, et al
EUROPEAN HEART JOURNAL 2010;:514-515

Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting
Anselmino M, Malmberg K, Mellbin L, Ryden L
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS 2010;11(1):87-94

Prediction of cardiovascular death and myocardial infarction by the QRS-T angle and T vector loop morphology after angioplasty in stable angina pectoris: an 8-year follow-up
Rubulis A, Bergfeldt L, Ryden L, Jensen J
JOURNAL OF ELECTROCARDIOLOGY 2010;43(4):310-7

Reducing cardiovascular risk in patients with type 2 diabetes mellitus
Nicholls Sj, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2010;:S1-

Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on Diabetes and the Heart
Euro Heart Survey Investigators, Anselmino M, Ohrvik J, Ryden L
EUROPEAN HEART JOURNAL 2010;31(24):3040-5

The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction
Hage C, Malmberg K, Ryden L, Wallander M
INTERNATIONAL JOURNAL OF CARDIOLOGY 2010;145(2):259-60

A gluco-metabolic risk index with cardiovascular risk stratification potential in patients with coronary artery disease
Anselmino M, Maimberg K, Ryden L, Ohrvik J
DIABETES & VASCULAR DISEASE RESEARCH 2009;6(2):62-70

A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes metlitus And Diastolic Dysfunction) study
Jarnert C, Landstedt-hallin L, Malmberg K, Melcher A, Ohrvik J, Persson H, et al
EUROPEAN JOURNAL OF HEART FAILURE 2009;11(1):39-47

Copeptin predicts and explains the association between IGFBP-1 and cardiovascular events in patients with type 2 diabetes and myocardial infarction
Catrina Sb, Mellbin Lg, Morgenthaler Ng, Botusan Ir, Ryden L, Ohrvik J, et al
DIABETOLOGIA 2009;:S522-S522

Effect of Postconditioning on Infarct Size in Patients With ST-elevation Myocardial Infarction
Sorensson P, Saleh N, Bouvier F, Bohm F, Settergren M, Caidahl K, et al
CIRCULATION 2009;120(18):S869-S869

Effect of Telmisartan on Renal Outcomes A Randomized Trial
Transcend Telmisartan Randomised, Mann Jfe, Schmieder Re, Dyal L, Mcqueen Mj, Schumacher H, et al
ANNALS OF INTERNAL MEDICINE 2009;151(1):1-10

Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study
Hage C, Norhammar A, Grip L, Malmberg K, Sarkar N, Svane B, et al
DIABETES & VASCULAR DISEASE RESEARCH 2009;6(2):71-9

Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study
Digami 2 Invest, Aas Am, Ohrvik J, Malmberg K, Ryden L, Birkeland Ki
DIABETES OBESITY & METABOLISM 2009;11(4):323-9

Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?
Ryden L, Malmberg K, Mellbin L
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM 2009;5(1):8-9

Letter by Settergren et al Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation"
Settergren M, Ryden L, Pernow J
CIRCULATION 2009;120(9):e68-author

Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease
Settergren M, Bohm F, Ryden L, Pernow J, Kalani M
JOURNAL OF INTERNAL MEDICINE 2009;266(5):492-8

Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial
Digami 2 Investigators, Mellbin Lg, Malmberg K, Waldenstrom A, Wedel H, Ryden L
HEART 2009;95(9):721-7

RIMONABANT IN CLINICAL PRACTICE (RICP). A SWEDISH MULTICENTER SURVEY IN PRIMARY CARE
Linder R, Birgersson Mo, De Faire U, Ridderstrale M, Rossner S, Sjostrom L, et al
VALUE IN HEALTH 2009;12(7):A386-A386

Strategies to enhance cardiovascular disease prevention in patients with diabetes
Anselmino M, Ryden L
CURRENT OPINION IN CARDIOLOGY 2009;24(5):461-7

The political power of heart doctors: with the European Heart Health Charter towards a European policy on cardiovascular disease
O'kelly S, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2009;:S58-60

Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?
Mellbin Lg, Ryden L, Malmberg K, Norhammar A, Wedel H
EUROPEAN HEART JOURNAL 2008;29(16):2058-2059

Cardiovascular prevention in patients with diabetes and prediabetes
Anselmino M, Gohlke H, Mellbin L, Ryden L
HERZ 2008;33(3):170-7

Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Settergren M, Bohm F, Ryden L, Pernow J
EUROPEAN HEART JOURNAL 2008;29(14):1753-60

Diabetes and the heart - Revisited
Ryden L, Tschope D, Dorr R
HERZ 2008;33(3):169-

Early detection and integrated management of dysglycemia in cardiovascular disease: A key factor for decreasing the likelihood of future events
Anselmino M, Mellbin L, Wallander M, Ryden L
REVIEWS IN CARDIOVASCULAR MEDICINE 2008;9(1):29-38

Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart
Euro Heart Survey Investigators, Anselmino M, Malmberg K, Ohrivik J, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2008;15(2):216-23

Glucose, insulin, and coronary heart disease: reply
Mellbin Lg, Malmberg K, Norhammar A, Ryden L
EUROPEAN HEART JOURNAL 2008;29(8):1076-1077

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart
Euro Heart Survey Investigators, Anselmino M, Oehrvik J, Malmberg K, Standl E, Ryden L
EUROPEAN HEART JOURNAL 2008;29(2):177-84

Implications of abnormal glucose metabolism in patients with coronary artery disease
Anselmino M, Wallander M, Norhammar A, Mellbin L, Ryden L
DIABETES & VASCULAR DISEASE RESEARCH 2008;5(4):285-90

Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes
Jarnert C, Melcher A, Caidahl K, Persson H, Ryden L, Eriksson Mj
EUROPEAN JOURNAL OF HEART FAILURE 2008;10(11):1080-7

Not only after myocardial infarction - Reply
Norhammar A, Ryden L
HEART 2008;94(7):935-935

Oral glucose tolerance test: A reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice - A report on repeated oral glucose tolerance tests from the GAMI Study
Wallander M, Ryden L, Malmberg K, Tenerz A, Norhammar A
DIABETES CARE 2008;31(1):36-8

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
Digami 2 Investigators, Mellbin Lg, Malmberg K, Norhammar A, Wedel H, Ryden L
EUROPEAN HEART JOURNAL 2008;29(2):166-76

The management of the type 2 diabetic patient with hypertension - too late and too little: Suggested improvements
Ryden L, Waeber B, Ruilope Lm, Mancia G, Volpe M, Holzgreve H, et al
BLOOD PRESSURE 2008;17(5-6):250-9

What are the risk factors for progression of coronary artery calcification in patients with type 2 diabetes?
Ryden L
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE 2008;5(7):370-1

Adjudication of serious heart failure in patients from PROactive
Ryden L, Thrainsdottir I, Swedberg K
LANCET 2007;369(9557):189-90

Fasting glucose predicts development of restenosis after PCI in patients with type 2 diabetes
Hage Ca, Norhammar A, Sarkar N, Svane B, Grip L, Ohrvik J, et al
DIABETOLOGIA 2007;:S496-S496

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary - The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
European Assoc Study Diabet Easd, Task Force Diabet Cardiovasc Dis European Soc Cardiology Esc, Esc Comm Practice Guidelines Cpg, Ryden L, Standl E, Bartnik M, et al
EUROPEAN HEART JOURNAL 2007;28(1):88-136

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text
Esc, Easd, Ryden L, Standl E, Bartnik M, Van Den Berghe G, et al
EUROPEAN HEART JOURNAL SUPPLEMENTS 2007;9(C):C3-C74

Hypuglycaemia does not increase long-term mortality or morbidity in diabetic patients with myocardial infarction: a report from the DIGAMI 2 trial
Mellbin Lg, Malmberg K, Waldenstrom A, Wedel H, Ryden L
DIABETOLOGIA 2007;:S82-S83

IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes
Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L, Brismar K
DIABETES CARE 2007;30(9):2343-8

Impact of time trends and increasing age on health behaviour of Swedish school children
Villard Lc, Ryden L, Ohrvik J, Stahle A
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2007;14(2):326-32

Increasing glucose levels and BMI predict future heart failure Experience from the Reykjavik Study
Thrainsdottir Is, Aspelund T, Gudnason V, Malmberg K, Sigurdsson G, Thorgeirsson G, et al
EUROPEAN JOURNAL OF HEART FAILURE 2007;9(10):1051-7

Leptin predicts glucose perturbations and future risk after acute myocardial infarction in patients without previously known diabetes
Wallander M, Soderberg S, Malmberg K, Norhammar A, Ryden L
DIABETOLOGIA 2007;:S494-S495

Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: A report from the Euro Heart Survey on Diabetes and the heart
Euro Heart Survey Investigators, Anselmino M, Bartnik M, Malmberg K, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2007;14(1):28-36

No effect of lipid lowering by simvastatin or simvastatin and ezetimibe on platelet function in patients with type 2 diabetes or impaired glucose tolerance and coronary artery disease
Malmstrom Re, Settergren M, Bohm F, Ryden L, Pernow J, Hjemdahl P
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2007;27(6):E80-E81

Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart
Euro Heart Survey Investigators, Bartnik M, Ryden L, Malmberg K, Ohrvik J, Pyorala K, et al
HEART 2007;93(1):72-7

Predictors of healthy behaviours in Swedish school children
Villard Lc, Ryden L, Stahle A
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2007;14(3):366-72

Rinnonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply
Ryden L, Standl E
EUROPEAN HEART JOURNAL 2007;28(11):1402-1402

Sex-related aspects on abnormal glucose regulation in patients with coronary artery disease
Euro Heart Survey Investigators, Dotevall A, Rosengren A, Bartnik M, Malmberg K, Ohrvik J, et al
EUROPEAN HEART JOURNAL 2007;28(3):310-5

The European Heart Health Charter: towards a healthier Europe
Ryden L, Martin J, Volqvartz S
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2007;14(3):355-6

Adjudication of serious heart failure in patients with type 2 diabetes and cardiovascular disease: Results from PROactive
Thrainsdottir I, Erdmann E, Ryden L, Spanheimer R
CIRCULATION 2006;114(18):849-849

Age and time trends in health behaviors among Swedish school age children from 1994 to 2003
Lindberg Lc, Stahle A, Ryden L
EUROPEAN HEART JOURNAL 2006;:107-107

An index of fasting glucose and HDL-cholesterol is a strong predictor for death and cardiovascular events in patients with coronary artery disease
Euro Heart Survey Investigators, Ohrvik J, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL 2006;:851-851

Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart
Euro Heart Survey Investigators, Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, et al
EUROPEAN HEART JOURNAL 2006;27(24):2969-74

Effect of insulin-glucose infusion on mortality following acute myocardial infarction in patients with diabetes: the diabetes and insulin-glucose infusion in acute myocardial infarction studies
Malmberg K, Rydén L
Seminars in thoracic and cardiovascular surgery 2006;18(4):326-9

Insulin-like growth factor binding protein-1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. A report from the DIGAMI 2 trial
Digami 2 Study Grp, Wallander M, Brismar K, Malmberg K, Norhammar A, Ohrvik J, et al
EUROPEAN HEART JOURNAL 2006;:839-839

Insulin-like growth factor binding protein-1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. A report from the DIGAMI 2 trial
Digami 2 Study Grp, Wallander M, Malmberg K, Norhammar A, Ohrvik J, Ryden L, et al
DIABETOLOGIA 2006;:31-32

Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction
Wallander M, Brismar K, Ohrvik J, Ryden L, Norhammar A
DIABETOLOGIA 2006;49(10):2247-55

Left atrial mechanics in Type 2 Diabetics
Eriksson Mj, Jarnert C, Jacobsson P, Ring M, Ryden L, Caidahl K, et al
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2006;47(4):120A-120A

Long-term influence of a health education programme on knowledge and health behaviour in children
Lindberg Lc, Stahle A, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2006;13(1):91-7

Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study
Wallander M, Bartnik M, Efendic S, Hamsten A, Malmberg K, Ohrvik J, et al
DIABETOLOGIA 2005;48(11):2229-35

Contemporary use of evidence-based treatment in patients with previous myocardial infarction compared with patients with diabetes in the European survey
Euro Heart Survey Investigators, Anselmino M, Bartnik M, Ryden L
CIRCULATION 2005;112(17):U910-U910

Development of implantable devices for continuous ambulatory monitoring of central hemodynamic values in heart failure patients
Implantable Hemodynamic, Bennett T, Kjellstrom B, Taepke R, Ryden L
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY 2005;28(6):573-84

FASTTRACK Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity
Digami 2 Investigators, Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, et al
EUROPEAN HEART JOURNAL 2005;26(7):650-61

Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study
Thrainsdottir Is, Aspelund T, Hardarson T, Maimberg K, Sigurdsson G, Thorgeirsson G, et al
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2005;12(5):465-71

Improved mortality after myocardial infarction in patients with diabetes mellitus
Norhammar A, Lindback J, Ryden L, Stenstrand U, Wallentin L
EUROPEAN HEART JOURNAL 2005;:666-666

Insulin-like growth factor-1 in patients with acute myocardial infarction but without previously known type 2 diabetes - report from the GAMI-trial
Wallander M, Ryden L, Brismar K, Norhammar A
DIABETOLOGIA 2005;:A396-A396

Long-term effects of lifestyle behavior change in coronary artery disease: Effects on recurrent coronary events after percutaneous coronary intervention
Lisspers J, Sundin O, Ohman A, Hofman-bang C, Ryden L, Nygren A
HEALTH PSYCHOLOGY 2005;24(1):41-8

Management of patients with type 2 diabetes after acute coronary syndromes
Bartnik M, Malmberg K, Rydén L
Diabetes & vascular disease research 2005;2(3):144-54

Models for immediate classification of gluco-metabolic state in patients with coronary artery disease
Euro Heart Survey Investigators, Ohrvik J, Bartnik M, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL 2005;:324-324

Oral glucose tolerance test or metabolic syndrome criteria to predict risk in patients with coronary heart disease?: reply
Bartnik M, Ryden L
EUROPEAN HEART JOURNAL 2005;26(6):623-624

Recognising abnormal glucose regulation in patients with coronary artery disease
Euro Heart Survey Investigators, Bartnik M, Ohrvik J, Ryden L, Pyorala K, Standl E, et al
EUROPEAN HEART JOURNAL 2005;:324-324

Secondary prevention in stable coronary artery disease-treatment targets in theory and practice
Euro Heart Survey Investigators, Anselmino M, Bartnik M, Ryden L
CIRCULATION 2005;112(17):U505-U505

The association between glucose abnormalities and heart failure in the population-based Reykjavik study
Thrainsdottir Is, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, et al
DIABETES CARE 2005;28(3):612-6

The relation between disturbed glucose regulation and heart failure - experiences from the Reykjavik Study
Thrainsdottir Is, Aspelund T, Sigurdsson G, Thorgeirsson G, Gudnason V, Hardarson T, et al
EUROPEAN HEART JOURNAL 2005;:656-656

Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus
Von Bibra H, Thrainsdottir Is, Hansen A, Dounis V, Malmberg K, Rydén L
Diabetes & vascular disease research 2005;2(1):24-30

Younger diabetic women are a high-risk group after myocardial infarction
Norhammar A, Lindback J, Stenestrand U, Wallentin L, Ryden L
EUROPEAN HEART JOURNAL 2005;:8-8

Abnormal glucose regulation in patients with coronary artery disease across Europe
Euro Heart Survey Investigators, Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, et al
DIABETOLOGIA 2004;:A61-A61

Abnormal glucose regulation in patients with coronary artery disease: Experience from the Euro Heart Survey
Euroheart Survey Investigators, Bartnik M, Ryden L, Ferrari R, Anna As, Malmberg Ka, et al
CIRCULATION 2004;110(17):795-795

Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls
Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, et al
JOURNAL OF INTERNAL MEDICINE 2004;256(4):288-97

Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes
Von Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Ryden L
HEART 2004;90(12):1483-4

Diabetes mellitus: The major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization
Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, et al
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2004;43(4):585-91

Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure
Thrainsdottir Is, Von Bibra H, Malmberg K, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 2004;44(1):101-8

Glucose abnormalities and heart failure - a dangerous combination. Results from the Reykjavik study
Thrainsdottir Is, Aspelund T, Gudnason V, Hardarson Th, Malmberg K, Sigurdsson G, et al
EUROPEAN HEART JOURNAL 2004;:438-438

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L
Diabetes & vascular disease research 2004;1(1):40-3

Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction
Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L
EUROPEAN HEART JOURNAL 2004;25(22):1990-7

Newly detected abnormal glucose tolerance - important predictor of long-term outcome myocardial infarction
Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L
EUROPEAN HEART JOURNAL 2004;:424-424

Patient access to medical technology across Europe
European Soc Cardiology, Ryden L, Stokoe G, Breithardt G, Lindemans F, Potgieter A
EUROPEAN HEART JOURNAL 2004;25(7):611-6

Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control
Nordlander M, Sjoquist Po, Ericsson H, Ryden L
CARDIOVASCULAR DRUG REVIEWS 2004;22(3):227-50

Promoting heart health - a European consensus
Shelley E, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2004;11(2):85-6

Six years follow-up of an implanted SvO(2) sensor in the right ventricle
Kjellstrom B, Linde C, Bennetta T, Ohlsson A, Ryden L
EUROPEAN JOURNAL OF HEART FAILURE 2004;6(5):627-34

The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular Systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)
Carmen Investigators, Remme Wj, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, et al
CARDIOVASCULAR DRUGS AND THERAPY 2004;18(1):57-66

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe - The Euro Heart Survey on diabetes and the heart
Euro Heart Survey Investigators, Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, et al
EUROPEAN HEART JOURNAL 2004;25(21):1880-90

Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)
Carmen Investigators & Co-ordi, Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, et al
EUROPEAN JOURNAL OF HEART FAILURE 2004;6(4):467-75

Brain natriuretic peptide and N terminal pro-brain natriuretic peptide for treatment monitoring in patients with left-ventricular systolic heart failure: a substudy of the CARMEN trial
Groenning Ba, Hildebrandt P, Riegger Ga, Nilsson Jc, Komajda M, Ryden L, et al
EUROPEAN HEART JOURNAL 2003;:361-361

Central hemodynamic responses during serial exercise tests in heart failure patients using implantable hemodynamic monitors
Ohlsson A, Steinhaus D, Kjellstrom B, Ryden L, Bennett T
EUROPEAN JOURNAL OF HEART FAILURE 2003;5(3):253-9

Closure or conservative management of atrial septal defects in adults: experiences from 25 years of follow-up of 325 patients
Rane Em, Forssell G, Ivert T, Ryden L
EUROPEAN HEART JOURNAL 2003;:357-357

Comparing multifactorial lifestyle interventions and stress management in coronary risk reduction
Sundin O, Lisspers J, Hofman-bang C, Nygren A, Ryden L, Ohman A
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE 2003;10(3):191-204

Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes
Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Ryden L, et al
DIABETES CARE 2003;26(10):2770-6

Does baseline heart rate determine the effect of carvedilol on ventricular remodelling in heart failure? Results of the CARMEN trial
Remme W, Riegger G, Ryden L, Bobbio M, Hildebrandt P, Soler-soler J, et al
EUROPEAN HEART JOURNAL 2003;:711-711

Effects of biventricular pacing on myocardial blood flow and oxygen consumption using carbon-11 acetate positron emission tomography in patients with heart failure
Braunschweig F, Sorensen J, Von Bibra H, Olsson A, Ryden L, Langstrom B, et al
AMERICAN JOURNAL OF CARDIOLOGY 2003;92(1):95-9

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
Kavianipour M, Ehlers Mr, Malmberg K, Ronquist G, Ryden L, Wikstrom G, et al
PEPTIDES 2003;24(4):569-78

Impaired glucose tolerance and diabetes mellitus; very common in patients with acute coronary syndromes
Bartnik M, Malmberg K, Nilsson G, Norhammar A, Tenerz A, Ryden L
EUROPEAN HEART JOURNAL 2003;:539-539

Lessons from the first patient with an implanted pacemaker: 1958-2001
Larsson B, Elmqvist H, Ryden L, Schuller H
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY 2003;26(1):114-24

Managing heart disease - Diabetes and the heart: compromised myocardial function - a common challenge
Bartnik M, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL SUPPLEMENTS 2003;5(B):B33-B41

Mode of death in heart failure: findings from the ATLAS trial
Atlas Study Grp, Poole-wilson Pa, Uretsky Bf, Thygesen K, Cleland Jgf, Massie Bm, et al
HEART 2003;89(1):42-8

Ongoing right ventricular hemodynarnics in heart failure - Clinical value of measurements derived from an implantable monitoring system
Adamson Pb, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, et al
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2003;41(4):565-71

Prediction of impaired glucose tolerance and manifest diabetes in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus
Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Ryden L, et al
DIABETOLOGIA 2003;:A376-A376

Tissue Doppler imaging for the early detection of myocardial dysfunction in patients with type 2 diabetes mellitus
Thrainsdottir Is, Von Bibra H, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL 2003;:55-55

Tissue Doppler Imaging for the early detection of myocardial dysfunction in patients with Type 2 diabetes mellitus
Thrainsdottir Is, Von Bibra H, Malmberg K, Ryden L
DIABETOLOGIA 2003;:A358-A358

Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction
Register Information Knowledge Swe, Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, et al
EUROPEAN HEART JOURNAL 2003;24(9):838-44

Arne Larsson 1915-2001 - Obituary
Ryden L, Schuller H, Larsson B
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY 2002;25(4):521-521

Association between N-terminal pro brain natriuretic peptide and left ventricular function in mild to moderate heart failure
Carmen Steering Comm Investigators, Groenning Ba, Riegger Ga, Hildebrandt R, Baumann M, Ryden L, et al
EUROPEAN HEART JOURNAL 2002;:269-269

Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure
Braunschweig F, Linde C, Eriksson Mj, Hofman-bang C, Ryden L
EUROPEAN HEART JOURNAL 2002;23(1):59-69

Does the degree of hyperglycemia influence diastolic myocardial function in patients with type 2 diabetes?
Von Bibra H, Dounis Vg, Hansen A, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL 2002;:89-89

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study
Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al
LANCET 2002;359(9324):2140-4

Pharmacological possibilities for protection against myocardial reperfusion injury
Wang Qd, Pernow J, Sjoquist Po, Ryden L
CARDIOVASCULAR RESEARCH 2002;55(1):25-37

Significant predictors of poor prognosis in women aged <= 65 years hospitalized for an acute coronary event
Al-khalili F, Svane B, Janszky I, Ryden L, Orth-gomer K, Schenck-gustafsson K
JOURNAL OF INTERNAL MEDICINE 2002;252(6):561-9

The need for resources for clinical research: the European Society of Cardiology calls for European, international collaboration
Bassand Jp, Martin J, Ryden L, Sirnoons M
LANCET 2002;360(9348):1866-9

Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I
Wang Qd, Segawa D, Ericsson H, Sjoquist Po, Johansson L, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 2002;40(2):228-34

Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: Part II
Segawa D, Sjoquist Po, Wang Qd, Gonon A, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 2002;40(3):339-45

Who are the enemies? Diabetes mellitus - a major risk factor for ischaemic myocardial injury: new directions in the management of acute coronary syndromes in the diabetic patient
Ryden L, Malmberg K
EUROPEAN HEART JOURNAL SUPPLEMENTS 2002;4(G):G21-G25

Biventricular pacing improves myocardial oxygen consumption during stress: a study using carbon-11 acetate positron emission tomography
Braunschweig F, Ryden L, Linde C, Sorensen J
EUROPEAN HEART JOURNAL 2001;:442-442

Cardiovascular critical event pathways for the progression of heart failure - A report from the ATLAS study
Atlas Investigators, Cleland Jgf, Thygesen K, Uretsky Bf, Armstrong P, Horowitz Jd, et al
EUROPEAN HEART JOURNAL 2001;22(17):1601-12

Central haemodynamic changes during standard exercise tests and daily living activities in patients with heart failure
Braunschweig F, Linde C, Bohm M, Cremers B, Adamson P, Magalsky A, et al
EUROPEAN HEART JOURNAL 2001;:33-33

Characteristics of chronic right venricular haemodynamics in heart failure measured by an implanatble monitoring system
Adamson Pb, Linde C, Reynolds Dw, Magalski A, Steinhaus D, Braunschweig F, et al
EUROPEAN HEART JOURNAL 2001;:503-503

Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor - Results of a 1 year multicentre feasibility study
Ohlsson A, Kubo Sh, Steinhaus D, Connelly Dt, Adler S, Bitkover C, et al
EUROPEAN HEART JOURNAL 2001;22(11):942-54

Diabetes mellitus - The most important risk factor for death and myocardial infarction in unstable CAD even after consideration of the extent of coronary lesions and beneficial effects of revascularisation
Malmberg K, Norhammar A, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, et al
CIRCULATION 2001;104(17):378-378

Diastolic myocardial function and myocardial microvasculature reserve improve with intense insulin treatment in type 2 diabetic patients
Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Ryden L
CIRCULATION 2001;104(17):369-370

Diastolic myocardial function and myocardial microvasculature reserve improve with intense insulin treatment in type 2 diabetic patients.
Von Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Ryden L
DIABETOLOGIA 2001;:A68-A68

Disturbed glucose metabolism is unexpectedly common in patients with myocardial infarction
Tenerz A, Norhammar A, Nilsson G, Ryden L, Malmberg K
DIABETOLOGIA 2001;:A304-A304

Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management
Ferrari R, Ryden L
EUROPEAN HEART JOURNAL SUPPLEMENTS 2001;3(L):L1-L2

Insulin treatment post myocardial infarction: The Digami study
Malmberg K, Norhammar A, Ryden L
DIABETES AND CARDIOVASCULAR DISEASE: ETIOLOGY, TREATMENT, AND OUTCOMES 2001;:279-84

Long-term effects of lifestyle behaviour change after PTCA: effects on the progression of CAD and on cardiac events
Hofman-bang C, Lisspers J, Sundin O, Nygren A, Ohman A, Ryden L
EUROPEAN HEART JOURNAL 2001;:140-140

Long-term follow-up with the Chronicle (R) implantable haemodynamic monitor: 12 months results from a multicentre feasibility trial in heart failure patients
Bennett T, Braunschweig F, Linde C, Adamson P, Magalski A, Kjellstrom B, et al
EUROPEAN HEART JOURNAL 2001;:534-534

Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications
Frykman V, Beerman B, Ryden L, Rosenqvist M
EUROPEAN HEART JOURNAL 2001;22(20):1954-9

Partnership in cardiovascular medicine - A key to success not only for professional organizations
Ryden L, Simoons Ml, Bassand Jp
EUROPEAN HEART JOURNAL 2001;22(20):1839-43

Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?
Ryden L, Gadler F
EUROPEAN HEART JOURNAL SUPPLEMENTS 2001;3(L):L21-L25

Pharmacological tools for the limitation of myocardial reperfusion injury - Experimental evidence
Ryden L, Sjoquist Po, Wang Wd
EUROPEAN HEART JOURNAL SUPPLEMENTS 2001;3(C):C28-C35

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure - Results from the ATLAS trial
Massie Bm, Armstrong Pw, Cleland Jgf, Horowitz Jd, Packer M, Poole-wilson Pa, et al
ARCHIVES OF INTERNAL MEDICINE 2001;161(2):165-71

Under-utilisation of evidence-based treatment a partial explanation to the unfavourable prognosis in diabetic patients with acute myocardial infarction
Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L
CIRCULATION 2001;104(17):626-626

Acute coronary findings at autopsy in heart failure patients with sudden death - Results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial
Uretsky Bf, Thygesen K, Armstrong Pw, Cleland Jg, Horowitz Jd, Massie Bm, et al
CIRCULATION 2000;102(6):611-6

Benefits of ACE inhibitors: what remains to be proven?
Ryden L, Malmberg K
EUROPEAN HEART JOURNAL SUPPLEMENTS 2000;2(I):L3-L7

[Biventricular pacing as a new therapeutic method in heart failure. An alternative for patients with intraventricular conduction disorders]
Braunschweig F, Gadler F, Linde C, Kjellström B, Rydén L
Lakartidningen 2000;97(40):4450-2

Biventricular pacing reduces hospital days in patients with severe congestive heart failure
Braunschweig F, Linde C, Gadler F, Ryden L
EUROPEAN HEART JOURNAL 2000;:483-483

Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: An experimental study with the ultrashort-acting calcium antagonist clevidipine
Segawa D, Sjoquist Po, Wang Qd, Gonen A, Nordlander M, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 2000;36(3):338-43

Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: The Stockholm Female Coronary Risk Study
Al-khalili F, Svane B, Wamala Sp, Orth-gomer K, Ryden L, Schenck-gustafsson K
AMERICAN HEART JOURNAL 2000;139(6):971-8

Clinical predictors of poor outcome in women recovering from acute coronary syndrome
Al-khalili F, Wamala Sp, Svane B, Orthgomer K, Ryden L, Schenck-gustafsson K
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2000;35(2):392A-392A

Contrast echocardiography
Von Bibra H, Bone D, Voigt Ju, Niklasson U, Wranne B, Ryden L
ZEITSCHRIFT FUR KARDIOLOGIE 2000;:86-96

Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus - Results from the DIGAMI study
Almbrand B, Johannesson M, Sjostrand B, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL 2000;21(9):733-9

Do all heart failure patients benefit from high dose lisinopril? Results from the ATLAS study
Atlas Investigators, Ryden L, Armstrong Pw, Cleland Jgf, Horowitz Jd, Massie Bm, et al
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2000;35(2):203A-203A

Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus - Results from the ATLAS trial
Atlas Study Grp, Ryden L, Armstrong Pw, Cleland Jfg, Horowitz Jd, Massie Bm, et al
EUROPEAN HEART JOURNAL 2000;21(23):1967-78

Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis
Pernow J, Bohm F, Johansson Bl, Hedin U, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 2000;:S418-20

European cardiology: 50 years
Verheugt Fwa, Martin Jf, Ryden L
LANCET 2000;356(9230):671-2

European role in global cardiology
Ryden L, Breithardt G, Poole-wilson P
LANCET 2000;355(9198):149-50

Haemostatic function in patients undergoing coronary artery bypass grafting: Peroperative perturbations and relations to saphenous vein graft closure
Moor E, Blomback M, Silveira A, Wiman B, Cederlund K, Bergstrand L, et al
THROMBOSIS RESEARCH 2000;98(1):39-49

Intracoronary ultrasound measurements in women with myocardial infarction without significant coronary lesions
Al-khalili F, Svane B, Di Mario C, Prati F, Mallus Mt, Ryden L, et al
CORONARY ARTERY DISEASE 2000;11(8):579-84

Joint efforts across national boundaries between professional organizations in cardiovascular medicine: One way into the future
Beller Ga, Ryden L
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2000;36(3):957-8

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study
Sculpher Mj, Poole L, Cleland J, Drummond M, Armstrong Pw, Horowitz Jd, et al
EUROPEAN JOURNAL OF HEART FAILURE 2000;2(4):447-54

Managing cardiovascular risk in patients with diabetes
Rydén L
Heart (British Cardiac Society) 2000;84 Suppl 1():i23-5

Managing cardiovascular risk in patients with diabetes
Ryden L
HEART 2000;:I23-I25

Reduction of hospital days by biventricular pacing
Braunschweig F, Linde C, Gadler F, Ryden L
EUROPEAN JOURNAL OF HEART FAILURE 2000;2(4):399-406

Renin-angiotensin system modulating treatments in the management of cardiovascular disease
Rydén L
Heart (British Cardiac Society) 2000;84 Suppl 1():i1-

Renin-angiotensin system modulating treatments in the management of cardiovascular disease
Ryden L
HEART 2000;:I1-I1

[Sudden death in an adult professional with no visible sickness--some reflections]
Rydén L, Bergfeldt L
Lakartidningen 2000;97(46):5372-4

ACE inhibitors or AT(1) receptor blockers in heart failure?
Ryden L
EUROPEAN HEART JOURNAL 1999;20(18):1287-9

Admission plasma glucose - Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients
Norhammar Am, Ryden L, Malmberg K
DIABETES CARE 1999;22(11):1827-31

A review of evidence of benefits from ACE inhibitors in heart failure compared with AT(1) receptor blockers and other therapies
Ryden L
EUROPEAN HEART JOURNAL SUPPLEMENTS 1999;1(Q):Q3-Q6

Behavioral effects of a comprehensive, multifactorial program for lifestyle change after percutaneous transluminal coronary angioplasty: A prospective, randomized, controlled study
Lisspers J, Sundin O, Hofman-bang C, Nordlander R, Nygren A, Ryden L, et al
JOURNAL OF PSYCHOSOMATIC RESEARCH 1999;46(2):143-54

Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine
Segawa D, Sjoquist Po, Nordlander M, Wang Qd, Gonon A, Ryden L
EUROPEAN JOURNAL OF PHARMACOLOGY 1999;380(2-3):123-8

Causes of sudden death in heart failure patients: Results from the ATLAS trial
Uretsky Bf, Thygesen K, Cleland Jgf, Horowitz Jd, Massie Bm, Packer M, et al
CIRCULATION 1999;100(18):580-580

Clinical-pathological correlation in the diagnosis of coronary disease as the cause of heart failure
Uretsky Bf, Thygesen K, Cleland Jgf, Horowitz Jd, Massie Bm, Packer M, et al
CIRCULATION 1999;100(18):860-860

Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT(1)-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs
Shimizu M, Wang Qd, Sjoquist Po, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 1999;34(4):512-7

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
Atlas Study Grp, Packer M, Poole-wilson Pa, Armstrong Pw, Cleland Jgf, Horowitz Jd, et al
CIRCULATION 1999;100(23):2312-8

Diabetes mellitus and congestive heart failure - Further knowledge needed
Solang L, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL 1999;20(11):789-95

Effects of organized aerobic group training in elderly patients discharged after an acute coronary syndrome. A randomized controlled study
Stahle A, Nordlander R, Ryden L, Mattsson E
SCANDINAVIAN JOURNAL OF REHABILITATION MEDICINE 1999;31(2):101-7

Effects of the angiotensin AT(1) receptor blocker candesartan on myocardial ischemic/reperfusion injury
Shimizu M, Sjoquist Po, Wang Qd, Ryden L
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 1999;:S137-42

Evidence-based management of heart failure: ACE inhibitors and AT(1) receptor blockers - Proceedings of a roundtable meeting held in New Orleans, USA, 6 March 1999 - Foreword
Ryden L, Hobbs Fdr
EUROPEAN HEART JOURNAL SUPPLEMENTS 1999;1(Q):Q1-Q2

Future perspectives on the management of angina pectoris
Ryden L
ATHEROSCLEROSIS 1999;:144-144

Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction - Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study
Malmberg K, Norhammar A, Wedel H, Ryden L
CIRCULATION 1999;99(20):2626-32

Guidelines: making the headlines or confined to the sidelines?
Bassand Jp, Ryden L
EUROPEAN HEART JOURNAL 1999;20(16):1149-51

Improved knowledge of antidiabetic treatment - a necessity for the modern cardiologist
Wikstrom G, Malmberg K, Ryden L
EUROPEAN HEART JOURNAL 1999;20(6):403-5

Improved physical fitness and quality of life following training of elderly patients after acute coronary events - A 1 year follow-up randomized controlled study
Stahle A, Mattsson E, Ryden L, Unden Al, Nordlander R
EUROPEAN HEART JOURNAL 1999;20(20):1475-84

Multifactorial evaluation of a program for lifestyle behavior change in rehabilitation and secondary prevention of coronary artery disease
Lisspers J, Hofman-bang C, Nordlander R, Ryden L, Sundin O, Ohman A, et al
SCANDINAVIAN CARDIOVASCULAR JOURNAL 1999;33(1):9-16

Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy
Pic Study Grp, Linde C, Gadler F, Kappenberger L, Ryden L
AMERICAN JOURNAL OF CARDIOLOGY 1999;83(6):903-7

Rapid return of left ventricular outflow tract obstruction and symptoms following cessation of long-term atrioventricular synchronous pacing for obstructive hypertrophic cardiomyopathy
Gadler F, Linde C, Ryden L
AMERICAN JOURNAL OF CARDIOLOGY 1999;83(4):553-7

Results of the ATLAS study
Ryden L
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 1999;:17-8

The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion
Shimizu M, Wang Qd, Sjoquist Po, Ryden L
CARDIOVASCULAR DRUGS AND THERAPY 1999;13(4):347-53

The angiotensin II AT(1)-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts
Shimizu M, Wang Qd, Sjoquist Po, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 1999;34(1):78-81

The careers of female cardiologists
Ryden L, Schenck-gustafsson K
EUROPEAN HEART JOURNAL 1999;20(17):1219-21

The effect of performing an autopsy on classifying the cause of death in patients with heart failure
Uretsky Bf, Cleland Jgf, Horowitz Jd, Massie Bm, Packer M, Poole-wilson Pa, et al
CIRCULATION 1999;100(18):861-861

Treatment of congestive heart failure - Has the time come for decreased complexity?
Ryden L, Remme Wj
EUROPEAN HEART JOURNAL 1999;20(12):867-71

Two-year results of a controlled study of residential rehabilitation for patients treated with percutaneous transluminal coronary angioplasty - A randomized study of a multifactorial programme
Hofman-bang C, Lisspers J, Nordlander R, Nygren A, Sundin O, Ohman A, et al
EUROPEAN HEART JOURNAL 1999;20(20):1465-74

Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury
Shimizu M, Wang Qd, Sjoquist Po, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 1998;32(2):231-8

[Better and cheaper care in heart failure. Efficient care programs save resources]
Rydén L
Lakartidningen 1998;95(24):2780-1

Calcium antagonists, appropriate therapy for diabetic patients with hypertension?
Malmberg K, Ryden L, Wedel H
EUROPEAN HEART JOURNAL 1998;19(9):1269-72

Coagulation factor V (Arg(506)-> Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting
Moor E, Silveira A, Van't Hooft F, Tornvall P, Blomback M, Wiman B, et al
THROMBOSIS AND HAEMOSTASIS 1998;80(2):220-4

Continuous ambulatory haemodynamic monitoring with an implantable system - The feasibility of a new technique
Ohlsson A, Nordlander R, Bennett T, Bitkover C, Kjellstrom B, Lee B, et al
EUROPEAN HEART JOURNAL 1998;19(1):174-84

Coronary thrombosis/thrombolysis in pigs: Effects of heparin, ASA, and the thrombin inhibitor inogatran
Uriuda Y, Wang Qd, Hatori N, Nordlander R, Sjoquist Po, Mattsson C, et al
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS 1998;39(2):81-9

Effect of intense insulin treatment on hyperglycaemia in diabetic patients with acute myocardial infarction.
Malmberg K, Norhammar A, Ryden L
DIABETOLOGIA 1998;:A42-A42

Excellent tolerability of high doses of lisinopril in the ATLAS trial
Massie Bm, Armstrong Pw, Cleland Jgf, Horowtiz Jjd, Packer M, Poole-wilson Pa, et al
CIRCULATION 1998;98(17):82-82

Health economic benefits of treating patients with heart failure with high dose lisinopril versus low dose: The ATLAS study
Cleland Jgf, Massie Bm, Packer M, Armstrong Pw, Horowitz Jd, Ryden L, et al
CIRCULATION 1998;98(17):135-135

Ischemia as a 'Trigger' for sudden death in patients with cardiomyopathy and heart failure secondary to coronary artery disease: Results from the ATLAS trial
Uretsky Bf, Armstrong Pw, Cleland Jg, Horowitz Jd, Massie Bm, Ryden L, et al
CIRCULATION 1998;98(17):199-199

Myocardioprotective effects of felodipine in an antihypertensive dosage: An experimental study in pigs
Shimizu M, Wang Qd, Sjoquist Po, Nordlander R, Ryden L
CARDIOVASCULAR DRUGS AND THERAPY 1998;12(1):37-45

Re-used pacemakers - as safe as new? A retrospective case-control study
Linde Cl, Bocray A, Jonsson H, Rosenqvist M, Radegran K, Ryden L
EUROPEAN HEART JOURNAL 1998;19(1):154-7

Re-use of devices in cardiology - Proceedings from a Policy Conference at the European Heart House, 5-6 February, 1998
Ryden L
EUROPEAN HEART JOURNAL 1998;19(11):1628-31

Risk markers of long-term outcome in patients with diabetes and acute myocardial infarction.
Ryden L, Norhammar A, Wedel H, Malmberg K
DIABETOLOGIA 1998;:A343-A343

Social relations and extent and severity of coronary artery disease - The Stockholm Female Coronary Risk Study
Orth-gomer K, Horsten M, Wamala Sp, Mittleman Ma, Kirkeeide R, Svane B, et al
EUROPEAN HEART JOURNAL 1998;19(11):1648-56

The importance of admission plasma glucose in non-diabetic patients with myocardial infarction.
Norhammar A, Ryden L, Malmberg K
DIABETOLOGIA 1998;:A342-A342

The lipid peroxidation inhibitor indenoindole H290/51 protects myocardium at risk of injury induced by ischemia-reperfusion
Shimizu M, Wang Qd, Sjoquist Po, Ryden L
FREE RADICAL BIOLOGY AND MEDICINE 1998;24(5):726-31

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients - A double-blind, randomized, dose-finding study
Grip L, Frison L, Wallentin L, Dellborg M, Grande P, Halinen M, et al
EUROPEAN HEART JOURNAL 1997;18(9):1416-25

[Care of heart failure may be better]
Rydén L
Lakartidningen 1997;94(25):2369-72

Distribution of knowledge
Ryden L, Poolewilson P, Breithardt G
EUROPEAN HEART JOURNAL 1997;18(10):1523-5

Lipoprotein(a) as a determinant of coronary heart disease in young women
Orthgomer K, Mittleman Ma, Schenckgustafsson K, Wamala Sp, Eriksson M, Belkic K, et al
CIRCULATION 1997;95(2):329-34

Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest
Gadler F, Linde C, Juhlindannfelt A, Ribeiro A, Ryden L
EUROPEAN HEART JOURNAL 1997;18(4):636-42

Markers of risk after acute myocardial infarction. A comparison of clinical variables, ambulatory and exercise electrocardiography, echocardiography, and stress echocardiography
Quintana M, Lindvall K, Brolund F, Storck N, Lindblad Le, Ryden L
CORONARY ARTERY DISEASE 1997;8(6):327-34

Mortality prediction in diabetic patients with myocardial infarction: Experiences from the DIGAMI study
Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H
CARDIOVASCULAR RESEARCH 1997;34(1):248-53

Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study (vol 34, pg 248, 1997)
Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H
CARDIOVASCULAR RESEARCH 1997;36(3):460-460

Restoration of atrial function after the maze procedure
Darpo B, Ryden L
EUROPEAN HEART JOURNAL 1997;18(3):360-1

The way ahead in the management of unstable coronary artery disease
Rydén L, Hamsten A
The American journal of cardiology 1997;80(5A):64E-67E

The way ahead the management of unstable coronary artery disease
Ryden L, Hamsten A
AMERICAN JOURNAL OF CARDIOLOGY 1997;:E64-E67

A low molecular weight, specific thrombin inhibitor, inogatran, versus heparin, in unstable coronary artery disease.
Grip L, Wallentin L, Dellborg M, Peer G, Halinen M, Held P, et al
CIRCULATION 1996;94(8):2512-2512

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis
Uriuda Y, Wang Qd, Grip L, Ryden L, Sjoquist Po, Mattsson C
CARDIOVASCULAR RESEARCH 1996;32(2):320-7

Calcium channel blockers or beta receptor antagonists for patients with ischaemic heart disease. What is the best choice?
Ryden L, Malmberg K
EUROPEAN HEART JOURNAL 1996;17(1):1-3

Cardioversion of atrial fibrillation - State of the Art, 1995
Ryden L, Malmberg K
SOUTH AFRICAN MEDICAL JOURNAL 1996;:C152-8

Coronary angioplasty in patients with unstable angina, with special reference to preceding treatment with antithrombin III and heparin
Grip L, Hellekant C, Herzfeld I, Malmberg K, Svane B, Szamosi A, et al
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS 1996;2(2):107-115

Coronary venous drug infusion in the ischaemic-reperfused isolated rat heart
Uriuda Y, Wang Qd, Li Xs, Sjoquist Po, Nordlander R, Ryden L
CARDIOVASCULAR RESEARCH 1996;31(1):82-92

Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction
Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H
EUROPEAN HEART JOURNAL 1996;17(9):1337-44

Hypertrophic obstructive cardiomyopathy
Ryden L
JOURNAL OF INTERVENTIONAL CARDIOLOGY 1996;9(4):307-309

Impaired myocardial function following chronic cobalt exposure in an isolated rat heart model
Haga Y, Clyne N, Hatori N, Hoffmanbang C, Pehrsson Sk, Ryden L
TRACE ELEMENTS AND ELECTROLYTES 1996;13(2):69-74

Implantable hemodynamic monitors in patients with heart failure: Initial results of a multicenter study
Kubo Sh, Ohlson A, Steinhaus Dm, Nordlander R, Adler Sw, Connelly Dt, et al
CIRCULATION 1996;94(8):802-802

Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model
Tadokoro H, Miyazaki A, Satomura K, Ryden L, Kaul S, Kar S, et al
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 1996;28(1):134-41

Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy
Gadler F, Linde C, Juhlindannfelt A, Ribeiro A, Ryden L
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 1996;27(5):1219-24

Long-term recording of cardiac output via an implantable haemodynamic monitoring device
Ohlsson A, Bennett T, Ottenhoff F, Bitkover C, Kjellstrom B, Nordlander R, et al
EUROPEAN HEART JOURNAL 1996;17(12):1902-10

[Pacemaker in hypertrophic obstructive cardiomyopathy. A new efficient treatment of heart disease]
Gadler F, Juhlin-dannfelt A, Linde C, Ribeiro A, Rydén L
Lakartidningen 1996;93(41):3566-8

[Surgical treatment of atrial septal defect. Good therapeutic alternative even for the elderly]
Forssell G, Rydén L, Rane Em
Lakartidningen 1996;93(39):3349-50

The effect of ventricular activation sequence on cardiac performance during pacing
Rosenqvist M, Bergfeldt L, Haga Y, Ryden J, Ryden L, Owall A
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY 1996;19(9):1279-86

BENEFICIAL-EFFECTS OF H290/51, A NEW LIPID-PEROXIDATION INHIBITOR, ON FUNCTIONAL RECOVERY AFTER ISCHEMIA AND REPERFUSION IN ISOLATED COLD-ARRESTED RAT HEARTS
Wang Qd, Uriuda Y, Li Xs, Nordlander R, Sjoquist Po, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 1995;25(6):924-9

DYNAMIC ONLINE VECTORCARDIOGRAPHY IMPROVES AND SIMPLIFIES IN-HOSPITAL ISCHEMIA MONITORING OF PATIENTS WITH UNSTABLE ANGINA
Dellborg M, Malmberg K, Ryden L, Svensson Am, Swedberg K
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 1995;26(6):1501-7

INFLUENCE OF CORONARY VENOUS RETROINFUSION AND VASODILATATION ON REGIONAL MYOCARDIAL BLOOD-FLOW MEASUREMENT WITH MICROSPHERES - AN ANALYSIS OF MICROSPHERE LOSS FROM ISCHEMIC AND REPERFUSED PORCINE HEARTS
Haga Y, Nordlander R, Sjoquist Po, Ryden L
ACTA PHYSIOLOGICA SCANDINAVICA 1995;153(1):13-20

MONITORING OF MIXED VENOUS OXYGEN-SATURATION AND PRESSURE FROM BIOSENSORS IN THE RIGHT VENTRICLE - A 24-HOUR STUDY IN PATIENTS WITH HEART-FAILURE
Ohlsson A, Beck R, Bennett T, Nordlander R, Ryden J, Astrom H, et al
EUROPEAN HEART JOURNAL 1995;16(9):1215-22

Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer
Ohlsson A, Bennett T, Nordlander R, Rydén J, Aström H, Rydén L
Journal of cardiac failure 1995;1(2):161-8

MYOCARDIAL RELEASE OF ENDOTHELIN (ET) AND ENHANCED ET(A) RECEPTOR-MEDIATED CORONARY VASOCONSTRICTION AFTER CORONARY-THROMBOSIS AND THROMBOLYSIS IN PIGS
Wang Qd, Uriuda Y, Pernow J, Hemsen A, Sjoquist Po, Ryden L
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 1995;26(5):770-6

PACING IN DILATED CARDIOMYOPATHY
Linde C, Ryden L
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY 1995;18(7):1341-5

Prognostic value of exercise stress testing versus ambulatory electrocardiography after acute myocardial infarction: A 3 year follow-up study
Quintana M, Lindvall K, Brolund F, Eriksson Sv, Ryden L
CORONARY ARTERY DISEASE 1995;6(11):865-73

PROGNOSTIC VALUE OF PREDISCHARGE EXERCISE STRESS ECHOCARDIOGRAPHY AFTER ACUTE MYOCARDIAL-INFARCTION
Quintana M, Lindvall K, Ryden L, Brolund F
AMERICAN JOURNAL OF CARDIOLOGY 1995;76(16):1115-21

RANDOMIZED TRIAL OF INSULIN-GLUCOSE INFUSION FOLLOWED BY SUBCUTANEOUS INSULIN-TREATMENT IN DIABETIC-PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION (DIGAMI STUDY) - EFFECTS ON MORTALITY AT 1 YEAR
Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 1995;26(1):57-65

RESULTS OF ATRIOVENTRICULAR SYNCHRONOUS PACING WITH OPTIMIZED DELAY IN PATIENTS WITH SEVERE CONGESTIVE-HEART-FAILURE
Linde C, Gadler F, Edner M, Nordlander R, Rosenqvist M, Ryden L
AMERICAN JOURNAL OF CARDIOLOGY 1995;75(14):919-23

[Thrombolysis is replaced by angioplasty. A change of strategy in the Swedish care of myocardial infarction?]
Herzfeld I, Grip L, Velander M, Rydén L
Lakartidningen 1995;92(7):622-625

Visa alla publikationer